---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-250357"
form_type: "8-K"
ticker: "ALXO"
cik: "0001810182"
company_name: "ALX ONCOLOGY HOLDINGS INC"
filed_at: "2023-10-04T23:59:59+00:00"
generated_at: "2026-06-10T04:55:33.525195+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# ALX Oncology reports positive interim Phase 2 ASPEN-06 data for evorpacept in HER2+ gastric cancer

## Summary
- Confirmed ORR 52% for evorpacept combo vs 22% control; median DOR not reached vs 7.4 months.
- First positive randomized data for any CD47 blocker in solid tumors; safety consistent with prior trials.
- Phase 3 ASPEN-06 initiation planned late 2024; final Phase 2 results expected Q2 2024.
- Stratification factors (2nd/3rd line, prior ENHERTU) prespecified and balanced per protocol.

## SEC filing metadata
- accession: 0001193125-23-250357
- form_type: 8-K
- ticker: ALXO
- cik: 0001810182
- company_name: ALX ONCOLOGY HOLDINGS INC
- filed_at: 2023-10-04T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1810182/000119312523250357/0001193125-23-250357-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1810182/000119312523250357/d539238d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-250357
- JSON: https://secwatch.observer/filing/0001193125-23-250357.json
- Plain text: https://secwatch.observer/filing/0001193125-23-250357.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.